Serum cystatin C has been proposed as a kidney biomarker to inform drug dosing. We conducted a systematic review to synthesize available data for the association between serum cystatin C and drug pharmacokinetics, dosing, and clinical outcomes in adults (!18 years). PubMed, Ovid MEDLINE, Ovid EMBASE, EBSCO CINAHL, and Scopus were systematically searched from 1946 to September 2017 to identify candidate studies. Studies of cystatin C as a predictor for acute kidney injury or for management of contrast-associated acute kidney injury were excluded. Also, studies were excluded if drug concentrations were unavailable and if a reference standard for drug dosing (eg, serum creatinine) was not concurrently reported. The outcomes of interest included drug clearance (L/h), concentrations (mg/L), target level achievement (%), therapeutic failure (%), and drug toxicity (%). We included 28 articles that evaluated 16 different medications in 3455 participants. Vancomycin was the most well-studied drug. Overall, cystatin Cebased estimated glomerular filtration rate (eGFR Cystatin C ) was more predictive of drug levels and drug clearance than eGFR Creatinine . In only one study were target attainment and outcomes compared between 2 drug-dosing regimens, one based on eGFR Creatinine-Cystatin C and one dosed with the Cockcroft-Gault creatinine clearance equation. Compared with eGFR Creatinine , use of eGFR Cystatin C to predict elimination of medications via the kidney was as accurate, if not superior, in most studies, but infrequently were data on target attainment or clinical outcomes reported. Drug-specific dosing protocols that use cystatin C to estimate kidney function should be tested for clinical application.
K idney function is a major determinant of medication safety. Approximately two-thirds of all drugs are eliminated by the kidneys, and up to 23% of medications used in hospitalized patients can be nephrotoxic. 1 Inappropriate use or dosing of medications eliminated via the kidney is associated with preventable medication errors in up to two-thirds of hospitalized patients. 2, 3 Serum creatinine is the most available endogenous marker used to estimate the glomerular filtration rate (GFR) and characterize the pharmacokinetics of medications in kidney disease. 4 The serum creatinine concentration is affected by many nonrenal determinants such as age, sex, and race, which are included as variables in GFR estimation equations to improve predictive performance. Unfortunately, in hospitalized patients several other factors that impact creatinine levels are incompletely accounted for in GFR estimation equations. 5 In particular, muscle mass variability in hospitalized patients can lead to both overestimation and underestimation of GFR because creatinine is the terminal byproduct of skeletal muscle catabolism.
In the past decade, important advances have been made in the study of novel renal biomarkers as tools to improve medication effectiveness and safety. One example, serum cystatin C, is an inexpensive endogenous marker of GFR that is less affected by age, sex, race, muscle mass, or dietary intake than creatinine. Its use has been widely validated across the spectrum of care and when combined with creatinine concentration has been found to more accurately predict measured GFR than either biomarker used alone. 6 Missing from the literature is a comprehensive characterization of the association between serum cystatin Cebased estimates of renal function and the prediction of drug elimination. Our objectives were to review the existing literature that compares kidney function based on serum cystatin C concentration to other estimates of kidney function for drug dosing in adults. We sought to qualitatively and quantitatively characterize the association between kidney function assessment tools and medication clearance, target level achievement, and clinical outcomes (ie, therapeutic failure and drug toxicity).
METHODS

This systematic review is reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement 7 and was conducted following an a priori established study protocol (PROSPERO CRD42017078043).
Study Selection Criteria
We included any trial up to September 2017 that assessed serum cystatin C for prediction of drug pharmacokinetics, plasma drug levels, dosing, and outcomes in adults (!18 years). Pharmacokinetic modeling analyses were eligible for inclusion. Studies that evaluated exclusively healthy volunteers or pediatric or neonatal patients or whose aim was to evaluate serum cystatin C for prediction or detection of acute kidney injury (AKI) or management of contrastassociated AKI were excluded. In addition, studies were excluded if they did not also report a reference standard for drug dosing (eg, estimated GFR [eGFR] with serum creatinine or estimated creatinine clearance [for clarity, collectively referred to as eGFRCreatinine in this article] or measured urinary creatinine clearance [mCL Cr ]). Articles in all languages were considered and screened.
Information Sources and Search Strategy
The search strategy was designed and conducted by an experienced research librarian (P.J.E.) with input from study investigators. We conducted a search of the following No randomized trials were identified by the search, and therefore, the NewcastleOttawa Scale (NOS) was selected to assess the quality of included studies. 8 The NOS is a scale designed to assess the quality of nonrandomized trials in 3 domains: selection, comparability, and outcome. Two reviewers (E.F.B., S.L.K.-G.) independently evaluated the quality of each study using a standardized NOS coding manual developed a priori for this study. For pharmacokinetic studies in which all patients received the drug and underwent serum concentration monitoring, the items "selection of nonexposed cohort" and "comparability of the cohorts" were omitted from the assessment (modified NOS). Disagreements were resolved by consensus and by referring to the study text.
Outcomes
The primary outcome of interest was observed drug clearance (L/h), which is the pharmacokinetic parameter most affected by GFR. Other pharmacokinetic end points (ie, observed concentrations in mg/L, goal concentration achievement [%], therapeutic failure [%], and medication toxicity [%]) were evaluated. All drugs and drug classes were included, and thus, these secondary outcomes were defined as appropriate for the drug type and the disease state under study. For example, for vancomycin, attainment of target trough concentrations would be the percentage of patients who achieve a steady state trough of 10 to 15 mg/L or 15 to 20 mg/L, individualized to the site of infection; therapeutic failure would be a failure to clinically or microbiologically cure an infection; and medication toxicity would be AKI or need for renal replacement therapy. Key definitions for study end points are outlined in Table 1 .
9-11
Data Synthesis and Analyses A qualitative assessment of the data was performed. When more than one study provided a correlation or coefficient of determination for an end point, randomeffects meta-analysis was performed to pool estimates across studies. Because most analyses had only 2 to 3 studies, Fisher r-to-z transformation was used to facilitate metaanalysis. 12 Statistical assessment of heterogeneity and publication bias was not possible or reliable. Heterogeneity was evaluated visually by inspecting point estimates and the overlap of confidence intervals. 13 Metaanalysis was performed using Comprehensive Meta-Analysis Software, version 3.0.
RESULTS
Study Identification and Characteristics
The initial literature evaluation identified 1834 references, of which 67 full-text articles were reviewed (Figure) . During the full-text screening, agreement between reviewers was excellent (average k coefficient for study inclusion, 0.91). The predominant reasons for study exclusion were a lack of reported information about drug clearance, drug concentrations or drug dosing, overlapping study samples, and a pediatric/neonatal study sample. Ultimately, 28 unique articles were qualitatively analyzed, 3 that explicitly characterized more than one drug 14-16 and 1 that described 2 unique subpopulations in detail (elderly and nonelderly). 17 For the remainder of the analyses, these will be described as separate studies (34 total). One drug, vancomycin, had sufficient data for reporting pooled estimates.
All included articles were observational studies or pharmacokinetic modeling analyses. One study compared target attainment and clinical outcomes between 2 groups: a dosing protocol with an eGFR based on creatinine and cystatin C with the Chronic Kidney Disease Epidemiology Collaboration equation (CKD EPI; eGFR Creatinine-Cystatin C ) and a dosing protocol based on the estimated There were originally 163 patients with digoxin concentrations, but 14 had undetectably low digoxin concentrations and were excluded from the original analysis; in the 149 patients remaining, the correlation between creatinine and cystatin C and digoxin concentrations were 0.34 and 0.35, respectively, but 55 of the patients in this group had levels drawn incorrectly. e 40 patients originally in the study, but only 18 patients were used in the correlation analysis for reasons that were not reported. creatinine clearance with the CockcroftGault equation. 18 The remaining 33 studies evaluated drug pharmacokinetics in a single group of patients. [14] [15] [16] Sixteen different medications were studied, the majority of which were antimicrobials. Vancomycin was the most well-characterized medication (N¼12), followed by digoxin (N¼3), and carboplatin (N¼3) (Supplemental Table 1 , available online at http://www. mayoclinicproceedings.org; Tables 2 and  3 ). Based on the modified NOS, studies were judged to have an overall low risk of bias (k coefficient for study quality between reviewers, 0.98; Supplemental Table 2 , available online at http://www. mayoclinicproceedings.org).
The individual characteristics of each study are described in Tables 2 and 3 . Included studies were published between 2004 and 2017 and included a total of 3455 participants (range, 7 to 678 participants per study). From the reported aggregate values, the mean AE SD age of participants was 64AE14 years, 2088 (60%) of included individuals were males (range, 0%-100%), and the mean weight was 69AE12 kg (unavailable for 3 studies). Three studies specifically characterized elderly patients, 1 that pertained to gentamicin 29 and 2 that evaluated vancomycin pharmacokinetics. 17, 39 One study described vancomycin use in patients with spinal cord injuries with resultant paraplegia or quadriplegia. 27 Among the 29 studies of hospitalized patients, 14 provided detail about the severity of illness and included 1168 intensive care unit patients (11%-100% of the included samples in these studies). 14, 15, [18] [19] [20] 24, 28, 29, 31, 32 The mean AE SD serum creatinine and cystatin C concentrations across the trials were 0.95AE0.31 mg/dL and 1.30AE0.25 mg/L, respectively. In the 8 studies that reported mCL Cr, the mean was 81AE21 mL/ min. 15, 19, 20, 22, 23, 31, 32 No studies reported measured GFR. The Cockcroft-Gault formula was the primary serum creatinineebased reference equation studied, and several approaches to estimating GFR from cystatin C (eGFR Cystatin C ) were reported, including the CKD EPI, Flodin, Larsson, Hoek, Macdonald, and Sjostrom equations. Infrequently were biomarkers studied in combination (7 studies that reported the CKD EPI eGFR Creatinine-Cystatin C ). 18, [25] [26] [27] [28] [29] 34 Outcomes for Certain Drugs and Classes Vancomycin. Twelve studies including 1806 patients evaluated cystatin C in the setting of vancomycin use (Supplemental Table 3 19, 23 but this analysis was associated with important heterogeneity. The remaining 6 studies focused on observed trough levels (mg/L). 17, 18, 20, 27, 28 Estimated GFR Cystatin C predicted vancomycin levels better than eGFR Creatinine (pooled R . Only one study evaluated the eGFR Creatinine-Cystatin C and found it to predict trough levels slightly better than the eGFR Cystatin C (R 2 , 0.58 vs 0.54) and significantly better than the eGFR Creatinine (R 2 , 0.27). 28 When individualized target trough achievement was compared, eGFR Cystatin C predicted trough achievement better than eGFR Creatinine , and the combination of the 2 biomarkers performed even better. 18, 28 The only study that used 2 patient groups to directly compare dosing models, found improved target trough achievement with an eGFR Creatinine-Cystatin C dosing model compared with a Cockcroft-Gault creatinine clearance dosing model (50% vs 28%, respectively) and no difference in treatment failure or toxicity. 18 Aminoglycosides. Five studies including 417 patients reported the association between eGFR Cystatin C and pharmacokinetics of 4 different aminoglycosides (gentamicin, tobramycin, amikacin, and arbekacin). 14, 29, 40 In the largest study (N¼260), the accuracy and precision of predictions were comparable for gentamicin clearance regardless of which renal biomarker was used in the eGFR equation, but the P30 (percentage of values within 30% of the reference; Table 1 ) was statistically superior with the eGFR Creatinine-Cystatin C (82%) compared with the eGFR Creatinine (77%; P¼.04) and with the eGFR Cystatin C (68%; P¼.003). 29 The eGFR Cystatin C more accurately and precisely predicted arbekacin levels than the eGFR Creatinine (R 2 , 0.89 vs 0.64). 40 No aminoglycoside studies evaluated mCL Cr or clinical outcomes.
b-Lactams. The pharmacokinetics of 4 different b-lactams (cefepime, meropenem, piperacillin/tazobactam, and cefuroxime) were evaluated in 5 studies with a total of 188 patients. In the 2 studies with mCL Cr , meropenem and piperacillin/tazobactam levels were best predicted by mCL Cr (R 2 , 0.76 and 0.75, respectively). The relationship between trough levels and eGFR Creatinine was not reported, but the R 2 for eGFR Cystatin C as a predictor of b-lactam trough levels was 0.31 and 0.45 for meropenem and piperacillin/tazobactam, respectively. 15 Results were variable in the 3 studies of b-lactam clearance. In the largest, which included 97 hospitalized patients, eGFR Cystatin C was a more significant predictor of cefuroxime clearance than eGFRCreatinine . 37 In 20 intensive care unit patients treated with cefepime, the best fit model for drug clearance included mCL Cr , followed by eGFR Creatinine . In 32 critically ill patients receiving meropenem, mCL Cr most improved the fit of clearance models, followed by eGFR Cystatin C and then eGFR Creatinine . 32 Achievement of target drug levels, clinical success, and drug toxicity were not reported in these studies.
Digoxin. Three studies evaluated 173 patients receiving digoxin in both the inpatient and outpatient settings. 35 Carboplatin. Three studies characterized the pharmacokinetics of carboplatin in 431 patients. 16, 22, 41 Two of the studies reported that the eGFR Creatinine-Cystatin C predicted drug clearance better than eGFR Creatinine . 16, 41 In a separate study of 29 patients, Holweger et al 22 compared predicted area under the concentration time curve with measured area under the concentration time curve after varying the renal assessment tool in the Calvert formula (administered carboplatin dose/[GFR þ 25]). Use of mCL Cr in the Calvert formula yielded the greatest bias and imprecision. Use of the eGFR Creatinine in the Calvert formula resulted in the least bias, but precision was comparable between the eGFR Creatinine and eGFR Cystatin C . 22 No carboplatin studies evaluated the combination of both serum biomarkers.
Subgroup and Sensitivity Analyses
Data were insufficiently detailed and too varied to conduct subgroup analyses in critically ill patients, the elderly, and those with known baseline alterations in body composition.
DISCUSSION
We conducted a systematic review of the use of serum cystatin C to estimate kidney function for drug dosing. The 34 included studies evaluated 3455 participants and 16 different medications. Vancomycin, a renally eliminated and nephrotoxic antimicrobial with activity against gram-positive pathogens, was the most studied drug. Overall, the eGFR Cystatin C was more predictive of drug levels and drug clearance than the eGFR Creatinine , and when available, the combined use of the biomarkers in the eGFR Creatinine-Cystatin C equation performed the best. Rarely was performance of eGFR compared with mCL Cr , no comparisons to measured GFR were noted, and only infrequently was there documentation of target attainment or clinical outcomes. The only study that compared 2 drug-dosing strategies head-to-head found a vancomycin dosing protocol based on eGFR Creatinine-Cystatin C significantly improved goal trough attainment compared with a CockcroftGault creatinine clearance dosing protocol with no difference in treatment failure or drug toxicity. 18 Our results are consistent with and expand upon the systematic review from Brou et al. 42 These authors described 16 studies with 7 medications published through 2014 and noted a correlation between cystatin C and drug elimination in all but one study. The study in which cystatin C was not associated with drug levels was 1 of 2 from their work excluded from the current systematic review because it referred exclusively to healthy volunteers. 43 The other study that we excluded evaluated pediatric patients. 44 Several studies have been published since 2014 that were included in the current analysis. Our focus was on eGFR rather than the absolute serum concentration of the biomarkers. Creatinine is affected by many factors other than kidney function that are, in part, accounted for in eGFR Creatinine equations. When comparing cystatin C with creatinine for drug dosing, regression models and pharmacokinetic calculations must include these nonrenal factors (eg, age, sex, race) either as part of the eGFR formula or as separate variables in the model to avoid inherently biasing the findings toward cystatin C. We provide greater detail about biomarker combinations, mCL Cr , and end points assessed. Since the landmark publication that reported that the CKD EPI eGFR Creatinine-Cystatin C predicted measured GFR with reduced bias and better precision than with either biomarker alone, there has been a greater emphasis on the use of creatinine and cystatin C in combination. We found that compared with eGFR with either biomarker alone, pharmacokinetics were best predicted by eGFR CreatinineCystatin C when studied, which may reflect a balancing of the nonrenal determinants of each marker when combined. It is unclear why, within a class (eg, b-lactams), drugspecific differences in the findings were noted despite similar degrees of renal drug clearance. This likely reflects a lack of in-study comparison between drugs using similar methods and small study samples, but this issue requires further evaluation. Only recently have studies begun to extend the pharmacokinetic findings of this previous literature to bedside care delivery and clinical outcomes. Overall, the strengths of this review include the comprehensive protocolized literature search and bias protection measures undertaken by reviewers (such as selecting studies, evaluating the quality of the studies, and extracting outcome data independently and in duplicate).
Several limitations should be considered when interpreting these findings. There was great variability in the study designs and reporting methods. We were, therefore, unable to quantitatively compare end points across key subgroups of interest. Because of the small number of included studies in each analysis, we were unable to statistically assess heterogeneity and publication bias. Publication bias is likely in systematic reviews like this one in which the body of evidence consists of small observational studies that do not require prior trial registration. Also, although the NOS is suitable for assessment of observational study quality, it may incompletely characterize the quality of pharmacokinetic studies. In 2015, analogous to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement for observational studies, 45 the ClinPK (Reporting Guidelines for Clinical Pharmacokinetic Studies) statement proposed a 24-item checklist to standardize reporting of pharmacokinetic analyses. 46 The work group found that only 45% of published pharmacokinetic studies included more than 80% of suggested items. 46 To our knowledge, a quality assessment tool similar to the NOS has not yet been proposed for pharmacokinetic evaluations. We recommend caution when generalizing these findings. Although not exclusively a study of hospitalized patients, the majority of the studies (29; 85%) reported data from individuals in the inpatient setting. Pediatric and neonatal patients were excluded because of the unique approaches to renal assessment in this population. In 2005, creatinine assay standardization occurred that led to slightly lower numerical values of creatinine and slightly higher corresponding eGFR Creatinine levels. 47 Nearly all of the included studies were published after 2005 but may have been affected by ongoing standardization efforts. Most of the approved dosing thresholds were developed with the Cockcroft-Gault creatinine clearance equation. When using estimates based on the CKD EPI or Modification of Diet in Renal Disease equations, the eGFR must be reexpressed in mL/min, the preferred unit for drug dosing; this factor was rarely reported in the included studies. It is most important when the body surface area deviates considerably from 1.73 m 2 as in morbidly obese patients or extremely underweight patients. It is unlikely that this factor substantially affected the observed results because the mean weight across studies was 69 kg, but it is an important consideration for future efforts.
These data highlight that indiscriminate application of new GFR assessment methods to existing dosing thresholds (eg, as part of the Calvert formula for carboplatin), whether based on creatinine, cystatin C, or both, could meaningfully alter resultant drug levels. Development of drug-specific algorithms are needed. 48 We recommend that for drugs with narrow therapeutic indices (eg, chemotherapeutics), high observed interpatient variability in drug levels (eg, blactams), or in high-risk populations (eg, elderly, critically ill), rigorous pharmacokinetic studies be performed and reported using standardized criteria. 46 Results from these studies could inform development of user-friendly dosing tools that then should be tested in pragmatic clinical trials. 18, 28 In the future, additional research is also necessary to characterize the clinical impact of cystatin Cebased dosing. The only study that directly compared clinical outcomes in patients dosed with vancomycin using cystatin C and nonecystatin C-based strategies included a broad sample of critically ill patients, not just those with resistant grampositive infections who would be most likely to benefit from optimized dosing. Also, future research should seek to understand the determinants of dissemination and implementation of cystatin Ceinclusive drug-dosing models in practice and the economic implications. Cystatin C measurement can be performed on existing laboratory platforms, and thus the primary costs related to its use are attributed to the reagent, which has been estimated at $4 per test. 49 
CONCLUSION
Compared with eGFR Creatinine , eGFR Cystatin C to predict renal elimination of medications was at least as accurate, if not superior, in most studies. Vancomycin was the most well-studied drug, and its target levels and elimination were better predicted by eGFR Cystatin C than eGFR Creatinine . Other drugs continue to require further investigation. Drug-specific dosing protocols based on cystatin should be developed and tested in clinical trials for application in clinical practice.
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